Limited time: 50% off your 1st month of membership! Start for $79 $39 →

Treatments

Resources

Who We Are

Work With Us

Get started

Limited time: 50% off your 1st month of membership! Start for $79 $39 →

Get started

Treatments

Medications

Resources

Who We Are

Work With Us

Get started

Limited time: 50% off your 1st month of membership! Start for $79 $39 →

Get started

Treatments

Medications

Resources

Who We Are

Work With Us

Get started

Limited time: 50% off your 1st month of membership! Start for $79 $39 →

Get started

Treatments

Medications

Resources

Who We Are

Work With Us

Get started

All articles

Tirzepatide vs Semaglutide: What Real-World Weight Loss Data Actually Shows

Reading time:

11 min

Author

Mochi Health Team

Published on

Aug 8, 2026

Updated on

Aug 10, 2026

Weight loss

Content

Key Takeaways

Ready to transform your health?

Get expert guidance and a personalized care plan designed around you.

Get started

Key Takeaways

In our own real-world analysis of 13,507 Mochi Health patients, about 3 in 5 people (59.1%) reached at least 10% total body weight loss by six months, with an average loss of 11.5%. This finding comes from a preprint study that has not yet been peer-reviewed.
Tirzepatide was linked to a substantially higher response rate than semaglutide, and that advantage held up even after accounting for differences between patients.
Real-world results run below the clinical-trial headlines, mostly because of a shorter six-month window, doses that are often still below the target, and everyday variation in engagement and consistency.
Reaching a therapeutic dose helps, but it explains only part of tirzepatide’s edge.
Both medications are effective options, and the right choice is a conversation to have with a provider.

When you’re comparing tirzepatide vs semaglutide for weight loss, you’ve probably run into the same headline everyone else has: people lose around 20% of their body weight on these medications. It’s a striking number. It’s also a number that came out of a tightly controlled clinical trial, and you might be wondering whether it will ever be your number.

That’s a fair thing to wonder. Trials are run under close to ideal conditions: carefully screened participants, maximum tolerated doses, and many months of intensive follow-up. Everyday life doesn’t look like that. So the real question for someone choosing between these two medications isn’t “what happened in the trial,” it’s “what happens to ordinary people, in ordinary care, in the first several months?”

This article answers that with our own data. We were curious what really happens once trial conditions fall away, so at Mochi Health we looked at 13,507 people who took one of these medications through our telehealth program and tracked how much weight they lost at six months. This wasn’t a tightly controlled clinical trial; it’s a picture of how real patients did in everyday care, which is exactly what makes it worth sharing. It compares how tirzepatide and semaglutide actually performed, shows the full range of outcomes rather than a single best-case average, and gets honest about why real-world numbers land where they do. For a broader look at how semaglutide and tirzepatide compare, it helps to start with what makes them different in the first place.

Continue reading to learn more about what real six-month weight loss looks like, which medication tends to deliver more, and what that means for the results you can plan around.

Key Takeaways

In our own real-world analysis of 13,507 Mochi Health patients, about 3 in 5 people (59.1%) reached at least 10% total body weight loss by six months, with an average loss of 11.5%. This finding comes from a preprint study that has not yet been peer-reviewed.
Tirzepatide was linked to a substantially higher response rate than semaglutide, and that advantage held up even after accounting for differences between patients.
Real-world results run below the clinical-trial headlines, mostly because of a shorter six-month window, doses that are often still below the target, and everyday variation in engagement and consistency.
Reaching a therapeutic dose helps, but it explains only part of tirzepatide’s edge.
Both medications are effective options, and the right choice is a conversation to have with a provider.

Continue reading to learn more about what real six-month weight loss looks like, which medication tends to deliver more, and what that means for the results you can plan around.

Tirzepatide vs Semaglutide: What’s the Actual Difference?

The main difference between tirzepatide vs semaglutide is how they work. Semaglutide activates one gut-hormone receptor (GLP-1), while tirzepatide activates two (GIP and GLP-1). That dual action is linked to greater weight loss in both clinical trials and everyday care. Both are effective medications, but they are not identical.

In plainer terms, semaglutide is a single GLP-1 receptor agonist, and tirzepatide is a dual GIP/GLP-1 receptor agonist. Both work largely by curbing appetite and slowing how fast your stomach empties, which makes it easier to eat less without feeling deprived. Tirzepatide simply pulls two levers where semaglutide pulls one.

The extra receptor is GIP, another hormone involved in how your body handles food and energy. You don’t need to memorize the biology to use it. The point is that tirzepatide engages more of the appetite-and-metabolism machinery at once, and that broader reach is the leading explanation for why it tends to move the scale more than semaglutide does.

That mechanistic difference isn’t just biochemistry trivia. It shows up as a real, measurable difference in how much weight people lose, which is what the rest of this article quantifies. It also doesn’t mean semaglutide is a lesser choice; it’s a highly effective medication with years of data behind it. The two simply sit at different points on the same spectrum.

One thing to be clear about up front: both semaglutide and tirzepatide are FDA-approved for weight management in their branded forms. Compounded medications are not approved or evaluated by the FDA for safety, effectiveness, or quality.That distinction matters, and it’s worth discussing with a provider so you understand exactly what you’re taking.

Tirzepatide vs Semaglutide: What’s the Actual Difference?

Tirzepatide & Semaglutide Weight Loss at Six Months

In our real-world study of 13,507 Mochi Health patients, the average weight loss at six months was 11.5% of body weight (median 11.3%), and about 3 in 5 people (59.1%) reached at least 10% of their starting weight. Most people lost a meaningful amount, though the results varied quite a bit from person to person.

That average is the honest anchor to keep in mind. It’s well below the trial headline, and that’s expected, but 11.5% at six months is still a substantial change for most people. Notice that the mean (11.5%) and median (11.3%) sit close together, which tells you the typical experience really is in that range rather than a few dramatic outliers pulling the number up. Because these are our own patients rather than a curated trial group, they’re realistic tirzepatide results and semaglutide results, not cherry-picked success stories.

The more useful picture, though, isn’t the average at all. It’s the full spread of who reached which milestone.

Here is the whole distribution we found, so you can place yourself on a realistic curve instead of anchoring only to the best case:

Weight-loss threshold at 6 months	Share of patients who reached it
≥5%	86.6%
≥10%	59.1%
≥15%	27.5%
≥20%	9.1%

Read this way, the picture is reassuring and realistic at the same time. The large majority of people (86.6%) lost at least 5%, which is the threshold often tied to health improvements. Reaching 20% by six months was uncommon (9.1%), which fits what we know about timing: weight is usually still coming off well past the six-month mark. If you want a week-by-week sense of the early curve, see how semaglutide weight loss timeline and tirzepatide weight loss week by week tend to unfold.

Tirzepatide & Semaglutide Weight Loss at Six Months

The more useful picture, though, isn’t the average at all. It’s the full spread of who reached which milestone.

Here is the whole distribution we found, so you can place yourself on a realistic curve instead of anchoring only to the best case:

Weight-loss threshold at 6 months	Share of patients who reached it
≥5%	86.6%
≥10%	59.1%
≥15%	27.5%
≥20%	9.1%

Is Tirzepatide Better Than Semaglutide for Weight Loss?

On weight loss, yes: we found tirzepatide was linked to a clearly higher response rate than semaglutide, and the gap held up even after accounting for differences between the two groups of patients. That doesn’t make semaglutide a weak choice, but if the single goal is average weight lost, tirzepatide came out ahead.

For context, the landmark head-to-head trial (SURMOUNT-5; Aronne et al., New England Journal of Medicine, 2025) found tirzepatide produced a 20.2% mean weight loss versus 13.7% for semaglutide at 72 weeks, under ideal trial conditions.The real question this study set out to answer is whether that advantage survives outside the trial, in messy everyday care read at just six months.

It did. We found tirzepatide’s ≥10% response rate was 16.0 percentage points higher than semaglutide’s before any statistical adjustment (68.8% vs 52.8%). To make the comparison fairer, we used propensity-score matching, which simply lines up similar patients so you’re comparing like with like rather than two different kinds of people. After matching on age, sex, BMI, weight, and other conditions, the gap was 18.1 points (69.6% vs 51.6%).

Real-world ≥10% response rate	Tirzepatide	Semaglutide	Difference
Unadjusted	68.8%	52.8%	+16.0 pts
Propensity-score matched	69.6%	51.6%	+18.1 pts

The nuance here matters, and it’s worth stating carefully. In most observational studies, a difference like this shrinks once you account for who chose what. This one didn’t; it actually widened slightly. That means the measured differences between patients don’t explain tirzepatide’s edge. This is an observational finding, not proof that the drugs are otherwise interchangeable. For an unmeasured factor to explain the gap away, it would have to be strongly linked to both the medication chosen and the result, on the order of a 2.0 risk ratio (we found an E-value of 2.04). That’s a high bar, which is part of why these real-world tirzepatide vs semaglutide results are notable. We’re careful not to overstate it: this is our best observational estimate under explicit assumptions, not a claim that the two drugs are otherwise identical.

This comparison is between tirzepatide and semaglutide as drug classes only. The study's authors state directly that they did not split the analysis by FDA-approved versus compounded formulation, and that the FDA-approved-versus-compounded question is addressed in a separate, companion study. As a result, these findings do not establish or support an efficacy comparison between compounded and FDA-approved versions of either medication.

Is Tirzepatide Better Than Semaglutide for Weight Loss?

Real-world ≥10% response rate	Tirzepatide	Semaglutide	Difference
Unadjusted	68.8%	52.8%	+16.0 pts
Propensity-score matched	69.6%	51.6%	+18.1 pts

Why are Real-World Results Lower Than the Clinical Trials?

First, the reassuring part: results below the trial numbers do not mean the medication is failing. Trials are engineered to show a drug at its absolute best. Real life isn’t, and the gap between the two is expected.

A few concrete factors explain most of the gap. Outcomes here were measured at six months, while the landmark trials read out around 16 to 17 months, when weight is often still coming off. Many real-world patients haven’t reached the maximum dose yet at the six-month mark. And diet, exercise, day-to-day engagement, and consistent access to treatment all vary from one person to the next, which affects whether people keep titrating up and stay on therapy.

The practical takeaway: plan around roughly 11.5% average loss at six months, not the trial’s best-case figure. It’s a more honest target, and hitting it is a real success. Small, sustainable changes help too; here are habits that improve your results without needing a higher dose.

What Affects Your Weight Loss on Tirzepatide or Semaglutide?

We built a model to see which factors were linked to reaching at least 10% weight loss. A few patterns stood out. Read these as associations from an observational study, not guarantees or levers you can simply pull.

Factor	Association with reaching ≥10% loss
Taking tirzepatide (vs semaglutide)	Higher odds (OR 2.10)
Female sex	Higher odds (OR 1.37)
Prior bariatric surgery	Higher odds (OR 1.36)
Comorbid diabetes	Lower odds (OR 0.84)
Higher baseline BMI (per unit)	Slightly lower odds of the relative % target (OR 0.98)

Taken together, these factors help explain why two people on the same medication can have different six-month results. The medication choice itself was the strongest signal in the model, but sex, surgical history, existing conditions, and starting weight all nudged the odds up or down. None of them is destiny, and most people reached a meaningful loss regardless of where they fell on these factors.

A word of caution on reading these: having diabetes, for example, marks a difference between groups, not something a person did wrong. It’s a way to personalize expectations, not a scorecard.

Response by Starting BMI

Response didn’t rise in a straight line with starting weight. We found 58.0% of people with a BMI under 30 reached ≥10% loss, peaking at 63.5% in the Obese I group (BMI 30 to 35), then easing to 59.6% in Obese II and 52.4% in Obese III. The intuitive reason: people with a higher starting BMI often lose more weight in absolute pounds, but that can be a smaller percentage of a larger starting weight, and percentage is what this threshold measures.

Does Reaching a Therapeutic Dose Explain the Difference?

Part of it, but not all of it. Tirzepatide patients reached a therapeutic dose far more often than semaglutide patients (98.5% vs 87.6%), and they refilled slightly more often too (a mean of 9.2 vs 8.3 refills). So it’s tempting to conclude that tirzepatide just gets titrated higher, and that’s the whole story.

It isn’t. We found that even among patients who did reach a therapeutic dose, tirzepatide still came out ahead by 14.2 percentage points (69.0% vs 54.8%). In other words, higher dosing accounts for only part of the gap; something about the medication itself appears to carry the rest.

The practical bridge is the same either way: getting to an effective dose, and staying on it consistently, is where a lot of the real-world response is won or lost. That’s exactly the part of the process that benefits from regular follow-up and steady titration support.

Tirzepatide vs Semaglutide: Which One Should You Consider?

Both medications work. Tirzepatide tends to produce more weight loss, and in our own data that advantage held up even after patient differences were accounted for. The realistic six-month anchor to plan around is roughly 11.5% on average, with a majority of people reaching at least 10%. That’s below the trial headlines, and it’s still a meaningful, health-relevant result.

What the data also makes clear is that the outcome isn’t decided by the prescription alone. Reaching a therapeutic dose, refilling consistently, and staying engaged over time all shape how much weight comes off. That’s the logic behind Mochi’s care model: unlimited provider visits plus ongoing monitoring and titration support, designed to help patients actually get to and stay on an effective dose.

If you’re trying to decide between these two medications, the best next step is a conversation. Mochi can connect you to a board-certified provider licensed in your state to talk through which option fits your history and goals. Check your eligibility to get started.

FAQs

Is tirzepatide better than semaglutide for weight loss?

For weight loss specifically, we found tirzepatide was linked to a higher response rate, and the advantage held up after accounting for patient differences. Better on average doesn’t mean better for everyone, though. You may also wonder about tirzepatide vs semaglutide, which is safer; our study focused on weight-loss outcomes rather than side effects, so it can’t answer that. A provider can weigh both with you.

How much weight can you lose on tirzepatide vs semaglutide?

Across all patients, we found an average six-month loss of 11.5%, with 59.1% reaching at least 10%. Response was higher on tirzepatide, but if you’re asking how much weight you can lose on semaglutide or how much weight you can lose on tirzepatide as a personal number, the honest answer is that it varies. Most people land somewhere in a wide range around that 11.5% average.

Can you switch from semaglutide to tirzepatide?

Many people do consider it, especially after seeing results like these. Whether it makes sense depends on your response so far, your history, and how you tolerate treatment, which is a decision to make with a provider. If you’re exploring it, this guide to switching from semaglutide to tirzepatide walks through what the transition can look like.

Are compounded tirzepatide and semaglutide FDA-approved?

No. Semaglutide and tirzepatide are FDA-approved for weight management in their branded forms, compounded medications are not approved or evaluated by the FDA for safety, effectiveness, or quality. If you’re prescribed a compounded medication, it’s worth understanding exactly what that means and discussing it directly with your provider.

References

Erly B, Raja S. Off-Trial: Real-World Weight Loss on Tirzepatide and Semaglutide. medRxiv preprint, 2026. doi:10.64898/2026.07.14.26357502. Available at: https://www.medrxiv.org/content/10.64898/2026.07.14.26357502v1.full-text

Disclaimer: This article is for educational purposes only and is not medical advice. Individual results are not guaranteed and may vary from person to person. Always consult your healthcare provider about your specific situation. Prescription medications require a provider's prescription. Compounded medications are not approved or evaluated by the FDA for safety, effectiveness, or quality. This article is based on a preprint study that has not been peer-reviewed, and the findings do not compare compounded to FDA-approved formulations.

Share this post

Weight loss

Mochi Health Team

Aug 8, 2026

Tirzepatide vs Semaglutide: What Real-World Weight Loss Data Actually Shows

Key Takeaways

Key Takeaways

Tirzepatide vs Semaglutide: What’s the Actual Difference?

Tirzepatide vs Semaglutide: What’s the Actual Difference?

Tirzepatide & Semaglutide Weight Loss at Six Months

Tirzepatide & Semaglutide Weight Loss at Six Months

Is Tirzepatide Better Than Semaglutide for Weight Loss?

Is Tirzepatide Better Than Semaglutide for Weight Loss?

Why are Real-World Results Lower Than the Clinical Trials?

What Affects Your Weight Loss on Tirzepatide or Semaglutide?

Response by Starting BMI

Does Reaching a Therapeutic Dose Explain the Difference?

Tirzepatide vs Semaglutide: Which One Should You Consider?

FAQs

Read next